As part of our ongoing commitment to building a greener and more responsible future, we are happy to announce the completion of the installation of 540 solar panels in one of our facilities. This action reinforces our dedication to sustainability and aligns with the Sustainable Development Goals (SDGs) outlined in the 2030 Agenda.
What does this mean for the environment?
With this installation, we are making a significant contribution to the environment by:
- Reducing our CO2 emissions by 130 tons annually, equivalent to the amount absorbed by over 6,000 trees.
- Achieving energy efficiency improvements of 18% to 30%, allowing us to use resources more responsibly.
- Generating clean, renewable energy, enough to power approximately 150 homes per year.
A commitment to positive change
This solar energy installation, with a capacity of 313.2 kWp, not only represents a significant reduction in our carbon footprint but also reaffirms our commitment to transforming our operations into a source of clean and sustainable energy. We have covered 1500 m² of our space with solar panels, marking a significant step in the fight against climate change.
Our commitment to sustainability does not stop here. We aim at driving projects for a brighter future where technology and respect for the environment go hand in hand. This is just the beginning of a series of initiatives that align our operations with sustainability and social responsibility principles.
Together, we are moving toward a greener, cleaner future for all!
News
October 01, 2024
We are moving towards a more sustainable future with solar energy!
Explore more
Insights
Digital Transformation at Viralgen
The article, written by María Iglesias, Digital & IT Head at Viralgen, explores how digitalization has transformed the manufacturing processes of adeno-associated viral (AAV) vectors at the company. Viralgen specializes in producing these viruses...
READ MORE
January 29, 2025
News
Viralgen and Axovia Partner to Manufacture an Investigational Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome (BBS) Patients
Collaborative effort will bring hope to BBS patients suffering from retinal degeneration through this investigational gene therapy. San Sebastián, Spain and London, Great Britain (January 22, 2025) - Viralgen and Axovia Therapeutics announced today...
READ MORE
January 22, 2025
News
Viralgen partners with Vallabh/Minikel Lab and Deverman Lab at the Broad Institute to advance gene therapy manufacturing hope for prion disease
Collaborative efforts focus on developing AAV gene therapy to treat prion disease. January 8, 2025. San Sebastian, Spain and Boston, Massachusetts Viralgen and two labs based in the Broad Institute of MIT (Massachusetts Institute of Technology) and...
READ MORE
January 21, 2025